Compare Amphastar Pharmaceuticals Inc (AMPH) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Marvell Technology Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Marvell Technology Inc trades at $217.79 (market cap $187.19B). The key difference: Marvell Technology Inc is far larger — about 216.7× Amphastar Pharmaceuticals Inc's market cap, and Marvell Technology Inc pays a 0.12% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MRVL | |
|---|---|---|
Market Cap | $863.95M | $187.19B |
Sector | Health | Technology |
52-Week High | $30.81 | $316.43 |
52-Week Low | $16.87 | $62.31 |
Enterprise Value | $1.26B | $188.63B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
MRVL trades at $218.72, up 3.89% today, with a bullish technical signal from moving averages but neutral oscillators. The stock has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $0.928. Revenue grew to $5.77B in 2025, though net income was negative. Analyst consensus is strongly bullish with an 82% buy rating and a $275.68 price target, implying 26% upside. Recent news highlights AI infrastructure product launches and institutional buying interest.
Outlook is positive driven by AI growth and earnings momentum, but high valuation multiples (P/E 75.16) and geopolitical risks from U.S.-China trade tensions pose challenges. Cash flow trends show improvement, with 2026 net cash flow projected at $3.0B. Investors should weigh strong analyst support against margin pressures and competitive threats in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
